Published

Announcement of two special issues: behavioural pharmacology of synaptopathies and psychedelic drugs

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Behavioural Pharmacology
Date: 2021-12-13
Source: OpenAlex
DOI: 10.1097/fbp.0000000000000662
PubMed: 35007231

Authors

Louk J. M. J. Vanderschuren Paul Willner Emily M. Jutkiewicz Bart Ellenbroek

Watch author

Derived topics and classifications

psilocybin Depression Anxiety PTSD Addiction Neuroplasticity Pharmacology Mechanism of Action Receptor Pharmacology Clinical Trial Review Article Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Announcement of two special issues: behavioural pharmacology of synaptopathies and psychedelic drugs2021-12-13

Related papers

Editorial: Psychedelic substances and neurological diseases: from basics to clinical applicationFrontiers in Pharmacology · 2026-03-15 Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric DisordersPsychiatry and Clinical Psychopharmacology · 2026-03-30 From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical PracticePharmacology Research & Perspectives · 2026-05-10 Psychedelics, entactogens and psychoplastogens for depression and related disorders.British journal of pharmacology · 2026-07-01 Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophreniaNeuropsychopharmacology · 2026-07-18 Psychedelics produce enduring enhancement of reward responsiveness in male rats.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-07-10 Announcement of special issue: ‘Behavioural pharmacology of ketamine and psychedelic drugs’Behavioural Pharmacology · 2026-05-06 A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populationsTherapeutic Advances in Psychopharmacology · 2026-02-28